Men's Health Briefing: October 6, 2026

The short version

Trustpilot's page for PeterMD, a provider in our directory, now says the business "goes against our guidelines" and is no longer visible. We lowered PeterMD's Atlas Score on October 1.

Otherwise a quiet week. We found no new FDA, DEA, FTC, or federal telehealth actions on testosterone, GLP-1s, ED or hair-loss drugs affecting men's health since our September 28 briefing.

The DEA's final telehealth prescribing rule is still under White House review. The temporary rules expire December 31, 2026.

This week

In the newsFirst reported by September 7 · Confirmed October 1, 2026

Trustpilot removes PeterMD's review profile

Trustpilot's page for PeterMD now says the business "goes against our guidelines and is no longer visible on Trustpilot." The profile previously showed nearly 14,000 reviews, most of them very positive. A review site, Vaccine Alliance, had reported the change by September 7, and we confirmed it ourselves on October 1. Trustpilot's notice doesn't say which guideline was involved, and it doesn't show a removal date, so we can't say when or why it happened.

PeterMD's homepage still shows a "4.9/5 Based on 20k+ Reviews" rating without naming an independent source for it. PeterMD is in our directory. Under our published scoring rules, a provider with no verifiable independent rating earns no reputation points, so PeterMD's reputation score fell from 2 to 0 and its Atlas Score from 3.5 to 3.1. We updated its review on October 1.

What it means for youA star rating on a company's own website isn't the same as one hosted by an independent review platform. When you compare providers, check ratings on the review platform itself, and look at more than one source. Our scoring method explains how we weigh reviews.

Sources: Trustpilot · PeterMD · Related: Our PeterMD review

We also checked FDA, DEA, and FTC announcements, federal telehealth policy, and news on the providers in our directory. Nothing else in the window affected treatment access, cost, safety, or health data for men's health readers. Medicare's October 1 billing change for rural health clinics and community health centers is administrative, and Medicare telehealth coverage remains in place through December 31, 2027.

What we're watching

The DEA's final telemedicine rule, which has been under review at the White House Office of Management and Budget since August 25, 2026. The federal regulatory agenda lists November 2026 for final action, ahead of the December 31 expiration of the temporary telehealth prescribing rules. If you get testosterone through a telehealth-only provider, nothing has changed yet. (NASCSA)

Testosterone for women, following the FDA's September 17 public workshop. Comments are open through October 19, 2026. (Public comment docket)

Testosterone label updates as manufacturers revise their prescribing information after the FDA's June 2026 request. See our TRT guide for what the research shows.

Compounded GLP-1 enforcement, including any follow-up to the FDA's September 18 warning letter to Empower Pharmacy, which the FDA made public on September 22. A warning letter states the FDA's concerns and is not a final finding. (Buchanan Ingersoll & Rooney · Related: our GLP-1 guide)

The FTC's case against Hims & Hers, filed July 29, 2026. The allegations have not been proven, and the company has said it disputes them. (FTC case page · Our Hims review)

The short version

This week

Trustpilot removes PeterMD's review profile

What we're watching

Get the Monday briefing by email